XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 5,138 $ 4,096
Short term deposit 1,014 6,085
Restricted cash 10 10
Prepaid clinical trial expenses and deferred clinical trial costs 1,962 1,728
Prepaid expenses and other current assets 154 365
Total current assets 8,278 12,284
Property and equipment, net 38 44
Total assets 8,316 12,328
Current liabilities:    
Trade payables 70 209
Employees and related liabilities 501 499
Accrued expenses 525 356
Total current liabilities 1,096 1,064
Non-current liabilities:    
Provision for uncertain tax positions 247 243
Total non-current liabilities 247 243
Total liabilities 1,343 1,307
Commitments and contingencies
Shareholders’ equity:    
Ordinary shares, NIS 0.3 par value; Authorized: 5,000,000 shares as of June 30, 2023, 2,666,667 as of December 31, 2022; Issued and outstanding: 1,090,452 and 1,081,755 shares as of June 30, 2023 and December 31, 2022, respectively.(*) 94 94
Additional paid-in capital 43,887 43,446
Accumulated deficit (37,008) (32,519)
Total shareholders’ equity 6,973 11,021
Total liabilities and shareholders’ equity $ 8,316 $ 12,328